TEV-48574 is an investigational medication being studied for its potential to help patients with moderate to severe ulcerative colitis or Crohn’s disease. The trial aims to evaluate how effective this medication is in inducing clinical remission for ulcerative colitis and achieving an endoscopic response for Crohn’s disease. The medication is administered every two weeks, and the study focuses on understanding its safety, tolerability, and how it behaves in the body over a 14-week period.

Crohn’s Disease – Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract, primarily affecting the small intestine and colon. It can cause a range of symptoms, including abdominal pain, diarrhea, fatigue, and weight loss. The inflammation can occur in patches and may penetrate deep into the layers of the bowel tissue. Over time, this can lead to complications such as strictures, fistulas, and malnutrition. The disease often progresses with periods of remission and flare-ups. The exact cause is unknown, but it is believed to involve a combination of genetic, environmental, and immune system factors.

Ulcerative Colitis – Ulcerative colitis is a chronic inflammatory bowel disease that primarily affects the colon and rectum. It is characterized by continuous inflammation of the innermost lining of the colon, leading to symptoms such as diarrhea, abdominal pain, and rectal bleeding. The inflammation usually begins in the rectum and can extend to involve the entire colon. Over time, the disease can cause complications like severe bleeding, perforation of the colon, and increased risk of colon cancer. The progression of ulcerative colitis involves alternating periods of remission and exacerbation. The exact cause is not fully understood, but it is thought to involve an abnormal immune response to gut bacteria.